华纳药厂 (688799)
Hunan Warrant Pharmaceutical Co., Ltd.
K-Line Chart
No K-line data available
Company NameHunan Warner Pharmaceutical Co., Ltd.
Listing Date2021-07-13
Issue Price30.82RMB
Registered Capital1313210k RMB
Legal RepresentativeHuang Bendong
Registered AddressLiuyang Biomedical Park, Hunan Province
IndustryChemical Pharmaceuticals
Main BusinessResearch, production, and sales of chemical APIs, chemical drug preparations, and traditional Chinese medicine preparations.
Company ProfileHunan Warner Pharmaceutical Co., Ltd. has cumulatively obtained 16 authorized and valid invention patents. It has undertaken nearly 30 projects at various levels, including major national and provincial science and technology projects, such as those from the National Development and Reform Commission (NDRC) and the Ministry of Science and Technology. Among them: the industrialization of Pazufloxacin Mesylate API was supported by the NDRC's High-tech Industrialization Special Project and the Ministry of Science and Technology's National Torch Program; the Class III new drug Docusate Sodium received the NDRC's Generic Chemical Drug Development Special Project. In 2011, the company was awarded the "National High-tech Industrialization Demonstration Project" by the NDRC. In 2019, the company was recognized by the Ministry of Industry and Information Technology as one of the first batch of "Little Giant" enterprises specializing in specific sectors, based on its leading product Colloidal Bismuth Pectin API and its preparations. Additionally, the company has received awards including the Hunan Provincial "Second Prize for Accelerating New Industrialization," two Changsha City Science and Technology Progress First Prizes, and two Second Prizes.
Stock Details
1. Key Indicators
- Total Shares(W): 13132.00
- Circulating A-Shares(W): 13132.00
- Earnings Per Share(RMB): 1.5800
- Net Assets Per Share(RMB): 15.1700
- Operating Revenue(W RMB): 108582.45
- Total Profit(W RMB): 21583.01
- **Net Profit Attributable to Parent(W RMB) **: 20712.36
- Net Profit Growth Rate(%): 30.75
- Weighted Return on Equity(%): 11.0100
- Operating Cash Flow Per Share(RMB): 1.5710
- Undistributed Profit Per Share(RMB): 7.3348
- Capital Reserve Per Share(RMB): 6.4780
2. Main Business
The main business covers:
- Research, production, and sales of chemical drug preparations
- Research, production, and sales of chemical pharmaceutical raw materials
- Research, production, and sales of traditional Chinese medicine preparations
3. Company Basic Information
- Company Name: Hunan Warrant Pharmaceutical Co., Ltd.
- Listing Date: 2021-07-13
- Industry: Pharmaceutical Manufacturing
- Address: Building C6-C7, Jinrui Lugu Technology Park, No. 28 Lutian Road, Yuelu District, Changsha City, Hunan Province
- Website: https://www.warrant.com.cn
- Company Profile: On September 30, 2015, Warrant Co., Ltd. obtained the "Enterprise Name Change Approval Notice" ((Xiang) Registration Internal Name Pre-approval No. [2015]15046) issued by the Hunan Provincial Administration for Industry and Commerce, pre-approving the proposed joint stock limited company.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Hunan Warrant Pharmaceutical Investment Partnership (Limited Partnership) | General Legal Person | 5223.68 | 39.78 |
| 2 | Everbright Pharmaceutical Health Theme Equity Initiated Securities Investment Fund Class A | Fund | 122.94 | 0.94 |
| 3 | China Europe Enjoy Life Hybrid Securities Investment Fund Class A | Fund | 108.91 | 0.83 |
| 4 | Huatai Securities Co., Ltd. | Securities Firm | 105.35 | 0.80 |
| 5 | Caitong Advantage Industry Rotation Hybrid Securities Investment Fund Class A | Fund | 46.38 | 0.35 |
| 6 | Caitong Science and Technology Innovation Theme Flexible Allocation Hybrid Securities Investment Fund (LOF) | Fund | 34.89 | 0.27 |
| 7 | Caitong Science and Technology Innovation Hybrid Securities Investment Fund Class A | Fund | 25.79 | 0.20 |
| 8 | China Merchants Yutai Hybrid Securities Investment Fund | Fund | 7.79 | 0.06 |
| 9 | Caitong Fusheng Multi-Strategy Hybrid Initiated Securities Investment Fund (LOF) Class A | Fund | 6.39 | 0.05 |
5. Concept Sectors
- Helicobacter Pylori
- Hepatitis Concept
- Innovative Drugs
- Synthetic Biology
- Margin Trading & Securities Lending
- High-Performance Stocks
- Securities Firms Heavy Positions
- Specialized, Refined, Special and New (SRSN) Enterprises
- Star Market 200
Remarks
- Data update date: 2025-09-30
- Data source: Public market information